Effect of low dose dopamine on early graft function in living unrelated kidney donors

Urology Journal

Volumn 9, Issue 1, 2012, Pages 389-396

  Hosseinzadeh, Hamzeh ^a,b   Golzari, Samad ^a,b   Abravesh, Mohammad ^a,b   Mahmoodpoor, Ata ^a,b   Aghamohammadi, Davood ^a,b   Zomorrodi, Afshar ^a,b   Hosseinzadeh, Parisa ^a,b  

^a TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Dopamine; Kidney function tests; Kidney transplantation; Tissue donors

Indexed keywords

ADRENERGIC RECEPTOR STIMULATING AGENT; CREATININE; DOPAMINE; UREA;

ADULT; ARTICLE; BLOOD; CHI SQUARE DISTRIBUTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DELAYED GRAFT FUNCTION; DIURESIS; DOUBLE BLIND PROCEDURE; DRUG EFFECT; HUMAN; KIDNEY FUNCTION TEST; KIDNEY TRANSPLANTATION; METHODOLOGY; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL; TIME; URINE;

ADULT; CHI-SQUARE DISTRIBUTION; CREATININE; DELAYED GRAFT FUNCTION; DIURESIS; DOPAMINE; DOUBLE-BLIND METHOD; HUMANS; KIDNEY FUNCTION TESTS; KIDNEY TRANSPLANTATION; MIDDLE AGED; SYMPATHOMIMETICS; TIME FACTORS; UREA; URINE; YOUNG ADULT;

EID: 84858243142     PISSN: 17351308     EISSN: 1735546X     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Wolfe RA, Ashby VB, Milford EL, et al. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med. 1999;341:1725-30.
2. Pratschke J, Wilhelm MJ, Kusaka M, et al. Brain death and its influence on donor organ quality and outcome after transplantation. Transplantation. 1999;67:343-8.
3. Matzinger P. Tolerance, danger, and the extended family. Annu Rev Immunol. 1994;12:991-1045.
4. van der Woude FJ. Graft immunogenicity revisited: relevance of tissue-specific immunity, brain death and donor pretreatment. Nephron. 2002;91:181-7.
5. Qureshi F, Rabb H, Kasiske BL. Silent acute rejection during prolonged delayed graft function reduces kidney allograft survival. Transplantation. 2002;74:1400-4.
6. Schnuelle P, Lorenz D, Mueller A, Trede M, Van Der Woude FJ. Donor catecholamine use reduces acute allograft rejection and improves graft survival after cadaveric renal transplantation1. Kidney Int. 1999;56:738-46.
7. Wagner M, Cadetg P, Ruf R, Mazzucchelli L, Ferrari P, Redaelli CA. Heme oxygenase-1 attenuates ischemia/ reperfusion-induced apoptosis and improves survival in rat renal allografts. Kidney Int. 2003;63:1564-73.
8. Perdue PW, Balser JR, Lipsett PA, Breslow MJ. "Renal dose" dopamine in surgical patients: dogma or science? Ann Surg. 1998;227:470-3.
9. Stephan H, Sonntag H, Henning H, Yoshimine K. Cardiovascular and renal haemodynamic effects of dopexamine: comparison with dopamine. Br J Anaesth. 1990;65:380-7.
10. Berger SP, Hunger M, Yard BA, Schnuelle P, Van Der Woude FJ. Dopamine induces the expression of heme oxygenase-1 by human endothelial cells in vitro. Kidney Int. 2000;58:2314-9.
11. Dragun D, Hoff U, Park JK, et al. Prolonged cold preservation augments vascular injury independent of renal transplant immunogenicity and function. Kidney Int. 2001;60:1173-81.
12. Brinkkoetter PT, Beck GC, Gottmann U, et al. Hypothermiainduced loss of endothelial barrier function is restored after dopamine pretreatment: role of p42/p44 activation. Transplantation. 2006;82:534-42.
13. Kapper S, Beck G, Riedel S, et al. Modulation of chemokine production and expression of adhesion molecules in renal tubular epithelial and endothelial cells by catecholamines. Transplantation. 2002;74:253-60.
14. Yard B, Beck G, Schnuelle P, et al. Prevention of cold-preservation injury of cultured endothelial cells by catecholamines and related compounds. Am J Transplant. 2004;4:22-30.
15. Schnuelle P, Berger S, de Boer J, Persijn G, van der Woude FJ. Effects of catecholamine application to brain-dead donors on graft survival in solid organ transplantation. Transplantation. 2001;72:455-63.
16. Schnuelle P, Lorenz D, Mueller A, Trede M, Van Der Woude FJ. Donor catecholamine use reduces acute allograft rejection and improves graft survival after cadaveric renal transplantation. Kidney Int. 1999;56:738-46.
17. Schnuelle P, Yard B, Braun C, et al. Impact of donor dopamine on immediate graft function after kidney transplantation. Am J Transplant 2004;4:419-26.
18. Grundmann R, Kindler J, Meider G, Stowe H, Sieberth HG, Pichlmaier H. Dopamine treatment of human cadaver kidney graft recipients: a prospectively randomized trial. Klin Wochenschr. 1982;60:193-7.
19. Schnuelle P, Gottmann U, Hoeger S, et al. Effects of donor pretreatment with dopamine on graft function after kidney transplantation: a randomized controlled trial. JAMA. 2009;302:1067-75.
20. Silverstein JH. Donor dopamine pretreatment and graft function after kidney transplantation. JAMA. 2010;303:230; author reply 1-2.
21. Wood KE, McCartney J. Management of the potential organ donor. Transplant Rev 2007;21:204-18.
22. Salahudeen AK. Cold ischemic injury of transplanted kidneys: new insights from experimental studies. Am J Physiol Renal Physiol. 2004;287:F181-7.
23. Gottmann U, Notheisen A, Brinkkoetter PT, et al. Influence of donor pretreatment with dopamine on allogeneic kidney transplantation after prolonged cold storage in rats. Transplantation. 2005;79:1344-50.
24. Wood KE, Becker BN, McCartney JG, D'Alessandro AM, Coursin DB. Care of the potential organ donor. N Engl J Med. 2004;351:2730-9.
25. Novitzky D, Cooper DK, Rosendale JD, Kauffman HM. Hormonal therapy of the brain-dead organ donor: experimental and clinical studies. Transplantation. 2006;82:1396-401.
26. De Los Angeles A, Banquero A, Bannett A, Raja R. Dopamine and furosemide infusion for prevention of post-transplant oliguric renal failure. Kidney Int. 1985;27:339-45.
27. Spicer ST, Gruenewald S, O'Connell PJ, Chapman JR, Nankivell BJ. Low-dose dopamine after kidney transplantation: assessment by Doppler ultrasound. Clin Transplant. 1999;13:479-83.